Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-02T19:25:41.610Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiveness of Antipsychotic Medication in the Treatment of BPD

Published online by Cambridge University Press:  23 March 2020

J. Stoffers-Winterling ,
O.J. Storebø ,
B. Völlm ,
J. Mattivi ,
S. Nielsen ,
M.L. Kielsholm ,
E. Simonsen  and
K. Lieb
J. Stoffers-Winterling
Affiliation:
University Medical Center of the Johannes Gutenberg University Mainz, Department of Psychiatry and Psychotherapy, Mainz, Germany
O.J. Storebø
Affiliation:
Psychiatric Research Unit, Psychiatric Department Region Zealand, Slagelse, Denmark
B. Völlm
Affiliation:
Division of Psychiatry and Applied Psychology University of Nottingham, Section of Forensic Mental Health, Nottingham, United Kingdom
J. Mattivi
Affiliation:
University Medical Center of the Johannes Gutenberg University Mainz, Department of Psychiatry and Psychotherapy, Mainz, Germany
S. Nielsen
Affiliation:
Psychiatric Research Unit, Psychiatric Department Region Zealand, Slagelse, Denmark
M.L. Kielsholm
Affiliation:
Psychiatric Research Unit, Psychiatric Department Region Zealand, Slagelse, Denmark
E. Simonsen
Affiliation:
University of Copenhagen Institute of Clinical Medicine, Psychiatry Region Zealand, Slagelse, Denmark
K. Lieb
Affiliation:
University Medical Center of the Johannes Gutenberg University Mainz, Department of Psychiatry and Psychotherapy, Mainz, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Though prescription is off-lable, “atypical” or “second-generation” antipsychotics (SGAs) are prevalently given to borderline personality disorder (BPD) patients. They have also been the focus of research on pharmacological agents in BPD in recent years, as the previous version of the relating cochrane systematic review shows.

Objectives

We are currently updating this cochrane systematic review on pharmacological interventions for BPD. First findings on the up-to-date evidence relating to SGAs will be presented.

Methods

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) according to cochrane collaboration standards. Any randomized comparisons of drug vs. placebo, drug vs. drug, or drug vs. a combination of drugs in adult BPD patients were eligible. Primary outcomes were BPD core pathology as depicted by DSM criteria. Secondary outcomes included associated pathology, i.e., depression and anxiety, general psychopathology severity and functioning as well as tolerability and safety. Two researchers selected trials, assessed quality and extracted data independently.

Results

The current RCT evidence on SGAs in BPD will be presented, and their use in everyday clinical care settings will critically be discussed.

Disclosure of interest

The authors declare that they have no competing interest.

Type
Symposium: Current evidence for pharmacological and psychological interventions in the treatment of borderline personality disorder–Findings from two-updated Cochrane reviews
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S47 - S48
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.